-
Views
-
Cite
Cite
Lonafarnib, American Journal of Health-System Pharmacy, Volume 78, Issue 9, 1 May 2021, Pages 755–757, https://doi.org/10.1093/ajhp/zxab034
- Share Icon Share
Extract
Lonafarnib is a farnesyltransferase inhibitor.
Class: 92:92 • Other Miscellaneous Therapeutic Agents (AHFS primary) Brands: Zokinvy®
Uses
Lonafarnib has the following uses:
...
Lonafarnib has the following limitations of use:
...
Dosage and Administration
General.
Lonafarnib is available in the following dosage form(s) and strength(s):
Capsules: 50 mg and 75 mg
Dosage.
It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Pediatric Patients.
Dosage and Administration in Pediatric Patients 12 Months of Age and Older.
...
Adults.
Dosage and Administration.
...
Cautions
Contraindications.
...
Warnings/Precautions.
Risk of Reduced Efficacy or Adverse Reactions Due to Drug Interactions.
Coadministration of lonafarnib with other drugs may result in clinically significant drug interactions. These drug interactions can lead to:
...
See the manufacturer’s labeling for instructions on preventing or managing these clinically significant drug interactions, including dosage recommendations. Consider the potential for drug interactions prior to and during lonafarnib therapy; review concomitant medications during lonafarnib therapy; and monitor for the adverse reactions.
Comments